Muutke küpsiste eelistusi

E-raamat: Handbook of Nuclear Medicine and Molecular Imaging: Principles and Clinical Applications [World Scientific e-raamat]

(Seoul Nat'l Univ, Korea), (Univ Of Texas, Usa), (Yokohama City Univ, Japan), (Yokohama City Univ, Japan)
  • Formaat: 474 pages
  • Ilmumisaeg: 04-Jul-2012
  • Kirjastus: World Scientific Publishing Co Pte Ltd
  • ISBN-13: 9789814366243
Teised raamatud teemal:
  • World Scientific e-raamat
  • Hind: 189,42 €*
  • * hind, mis tagab piiramatu üheaegsete kasutajate arvuga ligipääsu piiramatuks ajaks
Handbook of Nuclear Medicine and Molecular Imaging: Principles and Clinical ApplicationsSuurem pilt
  • Formaat: 474 pages
  • Ilmumisaeg: 04-Jul-2012
  • Kirjastus: World Scientific Publishing Co Pte Ltd
  • ISBN-13: 9789814366243
Teised raamatud teemal:
World Scientific e-raamatudRohkem infot World Scientific e-raamatute kohta
Raamatu kodulehekülg: http://www.worldscientific.com/worldscibooks/10.1142/8245#t=toc
Kim (nuclear medicine and diagnostic radiology, U. of Texas), Lee, Tateishi, and Baum supply trainees and practitioners of nuclear medicine, radiology, and general medicine with a handbook on nuclear medicine and molecular imaging techniques and clinical applications, including radionuclide therapy. In 19 chapters, radiologists and nuclear medicine specialists from Asia and the US explain basic nuclear physics and instrumentation; radiopharmaceutical chemistry; unexpected nuclear scan findings due to radiopharmaceutical, technical, or patient-related factors; scintigraphic imaging of cerebral spinal fluid; lymphoscintigraphy and nuclear venography; nuclear imaging for neurological disorders, urology, endocrinology, cardiology, pulmonary and gastrointestinal medicine, bones and joints, and esophageal, gastric, and pancreatic cancers; infection and inflammation, tumor, receptor-binding peptide, in vivo molecular, and in vitro imaging; and the therapeutic applications of radiopharmaceuticals. Annotation ©2013 Book News, Inc., Portland, OR (booknews.com)

This handbook will provide updated information on nuclear medicine and molecular imaging techniques as well as its clinical applications, including radionuclide therapy, to trainees and practitioners of nuclear medicine, radiology and general medicine.Updated information on nuclear medicine and molecular imaging are vitally important and useful to both trainees and existing practitioners. Imaging techniques and agents are advancing and changing so rapidly that concise and pertinent information are absolutely necessary and helpful.It is hoped that this handbook will help readers be better equipped for the utilization of new imaging methods and treatments using radiopharmaceuticals.
Preface v
Contributor List vii
Part I Basic Sciences
1(52)
Chapter 1 Basic Nuclear Physics and Instrumentation
3(18)
Jae Sung Lee
1.1 Basic Nuclear Physics
3(7)
1.1.1 Atom
3(1)
1.1.2 Radiation and radionuclide
4(1)
1.1.3 Radioactive decay
5(2)
1.1.4 Radioactivity and Half-life
7(2)
1.1.5 Interaction of radiation with matter
9(1)
1.2 Instrumentation
10(11)
1.2.1 Imaging procedures
10(1)
1.2.2 Gamma camera
10(2)
1.2.3 SPECT
12(2)
1.2.4 PET
14(3)
1.2.5 Hybrid systems
17(2)
Bibliography
19(2)
Chapter 2 Radiopharmaceutical Chemistry
21(32)
Yun-Sang Lee
2.1 Introduction
21(1)
2.2 The Use of Radiopharmaceuticals
21(1)
2.3 Production of Radionuclides
22(5)
2.3.1 Cyclotron-produced radionuclides
23(1)
2.3.2 Reactor-produced radionuclides
24(2)
2.3.3 Generator-produced radionuclides
26(1)
2.4 Radiolabeling Chemistry
27(7)
2.4.1 11C Chemistry
28(1)
2.4.2 18F Chemistry
29(1)
2.4.3 99mTc Chemistry
30(1)
2.4.4 Metallic radionuclide chemistry
31(2)
2.4.5 Radioiodine chemistry
33(1)
2.5 PET Radiopharmaceuticals
34(9)
2.5.1 PET radiopharmaceuticals for brain imaging
34(1)
2.5.1.1 Brain perfusion and metabolism
35(1)
2.5.1.2 Brain neurotransmitter systems
35(4)
2.5.1.3 β-Amyloid plaques imaging
39(1)
2.5.2 PET radiopharmaceuticals for heart imaging
39(1)
2.5.3 PET radiopharmaceuticals for tumor imaging
40(3)
2.6 99mTc-labeled Radiopharmaceuticals
43(4)
2.6.1 99mTc-labeled radiopharmaceuticals for bone imaging
44(1)
2.6.2 99mTc-labeled radiopharmaceuticals for brain imaging
44(1)
2.6.3 99mTc-labeled radiopharmaceuticals for heart imaging
45(1)
2.6.4 99mTc-labeled radiopharmaceuticals for kidney imaging
46(1)
2.6.5 99mTc labeled radiopharmaceuticals for liver imaging
46(1)
2.6.6 99mTc-labeled radiopharmaceuticals for blood flow
46(1)
2.7 Miscellaneous Radiopharmaceuticals
47(1)
2.8 Quality Control of Radiopharmaceuticals
48(5)
References
49(4)
Part II Clinical Applications
53(382)
Chapter 3 Unexpected Nuclear Scan Findings Due to Radiopharmaceutical, Technical, or Patient-Related Factors
55(56)
Usha A. Joseph
David Q. Wan
Asad Nasir
David Brandon
Isis W Gayed
Bruce J. Barron
3.1 Introduction
55(3)
3.2 Unexpected Nuclear Scan Findings From Radiopharmaceutical, Technical, or Patient Related Factors
58(53)
3.2.1 Discussion
58(2)
References
60(51)
Chapter 4 Nuclear Medicine in Neurological Disorder
111(42)
Yu-Keong Kim
Dong-Soo Kim
4.1 Cerebrovascular Disease
111(9)
4.1.1 Radiopharmaceuticals: Imaging protocol and analysis method
111(2)
4.1.2 Normal brain perfusion
113(2)
4.1.3 Brain perfusion SPECT in cerebrovascular disease
115(5)
4.2 SPECT and PET in Epilepsy
120(11)
4.2.1 Brain perfusion SPECT in epilepsy
120(4)
4.2.2 FDG-PET in epilepsy
124(7)
4.3 Dementia
131(22)
4.3.1 Alzheimer's disease and mild cognitive impairment
132(4)
4.3.2 FDG-PET in differential diagnosis of dementia
136(3)
4.3.3 Amyloid plaque imaging in AD
139(5)
References
144(9)
Chapter 5 Scintigraphic Imaging of Cerebral Spinal Fluid Flow, Blockage, and Leakage
153(10)
Franklin C. Wong
E. Edmund Kim
5.1 Introduction
153(2)
5.2 CSF Blockade
155(2)
5.3 CSF Leakage
157(2)
5.4 VP Shunts
159(1)
5.5 Discussion
160(3)
References
160(3)
Chapter 6 Nuclear Endocrinology
163(28)
Ho-Young Lee
June-Key Chung
E. Edmund Kim
6.1 Thyroid Gland
163(20)
6.1.1 Anatomy, physiology and metabolism
163(1)
6.1.1.1 Iodide metabolism and the physiology of thyroid
163(2)
6.1.1.2 Thyroid function test
165(3)
6.1.1.3 Thyroid scan
168(6)
6.1.1.4 FDG-PET in thyroid disease
174(1)
6.1.2 Radioactive iodine therapy
174(9)
6.2 Parathyroid Glands
183(3)
6.3 Adrenal Glands
186(5)
Bibliography
188(3)
Chapter 7 Nuclear Cardiac Imaging
191(16)
Jin-Chul Paeng
Dong-Soo Kim
7.1 Myocardial Perfusion Imaging
191(8)
7.1.1 Radiopharmaceuticals
191(2)
7.1.2 Stress study
193(1)
7.1.3 Imaging and analysis
194(2)
7.1.4 Application in CAD
196(3)
7.2 Myocardial Metabolism and Viability
199(4)
7.2.1 Energy metabolism of myocardium and radiopharmaceuticals
199(1)
7.2.2 Imaging protocol
200(1)
7.2.3 Myocardial viability assessment
201(2)
7.3 Other Cardiovascular Imaging
203(4)
7.3.1 Functional imaging
203(1)
7.3.2 Molecular imaging
204(1)
References
205(2)
Chapter 8 Pulmonary Nuclear Medicine
207(14)
E. Edmund Kim
Franklin Wong
8.1 Introduction
207(1)
8.2 Anatomy and Physiology
208(2)
8.3 Radiopharmaceuticals
210(1)
8.3.1 Gases
210(1)
8.3.2 Aerosols
210(1)
8.3.3 Particles
210(1)
8.4 Venous Thromboembolism
210(1)
8.5 Lung Imaging Techniques
211(10)
8.5.1 Ventilation imaging
211(3)
8.5.2 Perfusion imaging
214(1)
8.5.3 Pulmonary emboli
215(1)
8.5.4 VQ scan interpretation
216(3)
8.5.5 Post-test VQ investigation and follow-up of PE
219(1)
Bibliography
219(2)
Chapter 9 Gastrointestinal Nuclear Medicine
221(22)
Gi-Jeong Cheon
E. Edmund Kim
9.1 Introduction
221(1)
9.2 General Scintigraphy
221(6)
9.2.1 Gastric emptying scintigraphy
221(2)
9.2.2 GI bleeding scintigraphy
223(1)
9.2.3 Hepatobiliary scintigraphy
224(3)
9.2.4 Liver scintigraphy
227(1)
9.3 Oncologic Imaging in GI Tumors
227(16)
9.3.1 GI tracts
227(3)
9.3.2 Esophagus and stomach
230(2)
9.3.3 Colon and rectum
232(3)
9.3.4 GI stromal tumor
235(1)
9.3.5 Hepatobiliary tumors
235(3)
References
238(5)
Chapter 10 Nuclear Imaging of Esophageal, Gastric, and Pancreatic Cancers
243(24)
Hirofumi Shibata
Ukihide Tateishi
Tomio Inoue
10.1 Esophageal Cancer
243(8)
10.1.1 Introduction
243(1)
10.1.2 Discussion
244(1)
10.1.2.1 Staging
244(1)
10.1.2.2 T stage
245(1)
10.1.2.3 N stage
246(1)
10.1.2.4 M stage
247(1)
10.1.2.5 Detection of recurrent disease
248(1)
10.1.2.6 Monitoring of therapeutic response
249(1)
10.1.3 Conclusion
250(1)
10.2 Gastric Cancer
251(5)
10.2.1 Introduction
251(1)
10.2.2 Discussion
251(1)
10.2.2.1 Staging
251(1)
10.2.2.2 Primary tumor
252(1)
10.2.2.3 Lymph node metastases
253(1)
10.2.2.4 Peritoneal carcinomatosis
253(1)
10.2.2.5 Distant metastases
254(1)
10.2.2.6 Monitoring tumor response
254(1)
10.2.2.7 Local recurrence
254(1)
10.2.3 Conclusion
255(1)
10.3 Pancreatic Cancer
256(11)
10.3.1 Introduction
256(1)
10.3.2 Discussion
256(1)
10.3.2.1 Tumor Detection
256(3)
10.3.2.2 Staging
259(1)
10.3.2.3 Monitoring the Therapeutic Effect
260(1)
10.3.3 Conclusion
261(1)
References
261(6)
Chapter 11 Nuclear Urology
267(26)
Ukihide Tateishi
E. Edmund Kim
11.1 Introduction
267(1)
11.2 Renal Anatomy and Physiology
268(1)
11.3 Radiopharmaceuticals
269(1)
11.4 Radionuclide Renography
269(1)
11.5 Renal Cell Carcinoma
270(2)
11.6 Bladder Cancer
272(2)
11.7 Prostate Cancer
274(8)
11.7.1 18F-FDG-PET
274(3)
11.7.2 11C-choline PET
277(2)
11.7.3 18F-choline PET
279(1)
11.7.4 11C-Acetate PET
280(1)
11.7.5 Other tracers for PET
281(1)
11.8 Germ Cell Tumors
282(11)
11.8.1 Primary staging
282(1)
11.8.2 Surveillance
282(1)
11.8.3 Assessment of treatment response
283(4)
11.8.4 Prognostic prediction
287(1)
References
287(6)
Chapter 12 Bone and Joint Nuclear Imaging
293(34)
Seok-ki Kim
12.1 Introduction
293(1)
12.2 Agents for Skeletal NI
294(2)
12.2.1 Agents for osteoblastic activity
294(1)
12.2.2 Selective skeletal agent
295(1)
12.3 Imaging Technique and New Scanners
296(2)
12.4 Normal Appearance and the Perception and Interpretation of Abnormal Findings
298(5)
12.4.1 Normal variants and perception of abnormal findings
298(1)
12.4.2 Disease-specific patterns and characteristics
299(4)
12.5 Clinical Applications
303(24)
12.5.1 Skeletal metastasis
303(1)
12.5.1.1 Breast cancer
303(3)
12.5.1.2 Lung cancer
306(2)
12.5.1.3 Thyroid cancer
308(1)
12.5.1.4 Renal cell cancer
309(1)
12.5.1.5 Multiple myeloma
310(1)
12.5.1.6 Prostate cancer
311(1)
12.5.2 Primary bone tumors: Benign and malignant
312(2)
12.5.3 Metabolic bone diseases
314(3)
12.5.4 Trauma and sports injury
317(2)
12.5.5 Inflammation and infection of the skeletal system
319(1)
12.5.5.1 Osteomyelitis
319(1)
12.5.5.2 Osteomyelitis in patients with diabetes
320(1)
12.5.5.3 Orthopedic implant infections
320(2)
References
322(5)
Chapter 13 Lymphoscintigraphy and Nuclear Venography
327(6)
E. Edmund Kim
Franklin Wong
Reference
332(1)
Chapter 14 Infection and Inflammation Imaging
333(20)
So-Won Oh
Ukihide Tateishi
Yu-Kyeong Kim
Jin-Chul Paeng
E. Edmund Kim
14.1 Introduction
333(1)
14.2 Pathophysiology of Infection and Inflammation
334(1)
14.3 Targeting Strategies for Infection and Inflammation Imaging
335(1)
14.3.1 Increase in vascular permeability
335(1)
14.3.2 Endothelial activation
335(1)
14.3.3 Leukocyte accumulation
335(1)
14.3.4 Microorganisms
336(1)
14.4 Radiopharmaceuticals
336(4)
14.4.1 Radiolabeled leukocytes
336(1)
14.4.2 67Ga
337(2)
14.4.3 FDG
339(1)
14.4.4 Radiolabeled antibody
339(1)
14.4.5 99mTc-ciprofloxacin
339(1)
14.5 Clinical Applications
340(5)
14.5.1 Fever of unknown origin
340(1)
14.5.2 Immunodeficiency patient
341(1)
14.5.3 Inflammatory bowel disease
342(1)
14.5.4 Prosthesis infection
343(1)
14.5.5 Respiratory disease
343(1)
14.5.6 Cardiovascular system
344(1)
14.5.7 Other applications
344(1)
14.6 PET/CT of Inflammation
345(6)
14.6.1 Introduction
345(1)
14.6.2 Mechanism of uptake in inflammatory processes
346(1)
14.6.3 Disease activity and accumulation
347(1)
14.6.4 Limitations
348(1)
14.6.5 Tracers
349(2)
14.7 Conclusion
31
References
351(2)
Chapter 15 Tumor Imaging
353(16)
Ukihide Tateishi
E. Edmund Kim
15.1 Introduction
353(1)
15.2 Glucose Metabolism
353(1)
15.3 Glucose Transporter
354(1)
15.4 Uptake by Tumor Cells
355(1)
15.5 Blood Flow and Uptake
355(2)
15.6 Specific Pitfalls of PET/CT
357(1)
15.7 PET/CT of Hematologic Malignancies
358(8)
15.7.1 Introduction
358(1)
15.7.2 Staging
358(2)
15.7.3 Response monitoring
360(2)
15.7.4 Evaluation of prognosis
362(1)
15.7.5 Proliferative activity in malignant lymphoma
362(4)
15.8 Conclusion
366(3)
References
366(3)
Chapter 16 Receptor-Binding Peptide Imaging
369(12)
E. Edmund Kim
Richard Baum
16.1 Receptor Targeting in Oncology
371(2)
16.2 Somatostatin
373(1)
16.3 Vasoactive Intestinal Peptide
374(1)
16.4 Bombesin, Calcitonin, and Cholecystokinin
375(1)
16.5 Epidermal Growth Factor and Vitronectin Receptor
375(1)
16.6 Infectious and Inflammatory Imaging Peptides
376(1)
16.7 Thrombus Imaging Peptides
377(4)
References
378(3)
Chapter 17 In vivo Molecular Imaging
381(14)
Keon Wook Kang
17.1 Molecular Imaging and Nuclear Medicine
382(1)
17.2 Molecular Imaging and Positron Emission Tomography
383(2)
17.3 Reporter Gene Imaging
385(2)
17.4 Multimodal Molecular Imaging
387(2)
17.5 Molecular Imaging Using Nanoparticles
389(1)
17.6 Translational Research Using Molecular Imaging
390(5)
References
392(3)
Chapter 18 In Vitro Nuclear Medicine Tests
395(6)
E. Edmund Kim
18.1 Carbon-14 Urea Breath Test
395(2)
18.2 Schilling Test
397(1)
18.3 Blood Volume
398(1)
18.4 Cell Survival and Sequestration
399(2)
References
400(1)
Chapter 19 Therapeutic Applications of Radiopharmaceuticals
401(34)
Franklin C. Wong
E. Edmund Kim
19.1 Introduction to Radionuclide Therapy
401(1)
19.2 Radiopharmaceuticals for Therapy
402(5)
19.2.1 Therapeutic radionuclides
402(1)
19.2.2 The ranges of emitted particle radiation in the tissue
403(1)
19.2.3 Biodistribution of radiopharmaceuticals determines residence time of radionuclides in the target tissue and non-target tissues
403(1)
19.2.4 Dosimetry of radiopharmaceuticals
404(1)
19.2.5 Radionuclides of therapeutic interest
404(3)
19.3 Systemic Radionuclide Therapies in Practice
407(8)
19.3.1 Polycythemia vera using 32P
407(1)
19.3.2 Hyperthyroidism and Graves disease using 131I
408(1)
19.3.3 Thyroid cancer remnants using 131I
409(2)
19.3.4 Refractory lymphomas using 90Y- ibritumomab tiuxetan and 131I
411(1)
19.3.5 Painful osseous metastases using 89Sr chloride and 153Sm-EDTMP
412(2)
19.3.6 Neuroendocrine tumor using 111In-octreotide, 90Y- DOTA-TOC and 177Lu-DOTA-TOC
414(1)
19.4 Locoregional Radionuclide Therapies
415(10)
19.4.1 Concerns specific to locoregional radionuclide therapies
415(1)
19.4.1.1 High efficacy
415(2)
19.4.1.2 Toxicity and interaction with host
417(1)
19.4.1.3 Dosimetry modeling and limits
418(1)
19.4.2 The practice of locoregional radionuclide cancer therapy
418(1)
19.4.2.1 Intraarterial palliative treatment of liver cancers
418(2)
19.4.2.2 Intrathecal treatment of meningeal carcinomatosis
420(1)
19.4.2.3 Pleural and pericardial effusion
421(1)
19.4.2.4 Peritoneal carcinomatosis
422(1)
19.4.2.5 Intracavitary treatment of cystic brain tumors
423(1)
19.4.2.6 Interstitial radionuclide therapies
424(1)
19.5 Conclusion
425(10)
References
425(10)
Index 435
Püsilink: https://www.kriso.ee/db/9789814366243_pe.html